Eris Lifesciences Ltd · NSE:ERIS
Eris Lifesciences — Q3 FY23 Earnings Presentation
21 slides from Eris Lifesciences's earnings presentation, Jan 17, 2023
Slide 1: Cover letter to stock exchanges
Date: 17 January 2023 To To BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza Dalal Street Bandra Kurla Complex Mumbai- 400001 Bandra (E) Mumbai-400051 Security Code: 540596 Symbol: ERIS SUBJECT: INVESTOR PRESENTATION Dear Sir/Madam, Pursuant to the requir
Slide 2: Eris Lifesciences Limited Q3 FY23 and 9M FY23 Investor Presentation
Eris ERIS LIFESCIENCES LIMITED Q3 FY 23 and 9M FY 23 INVESTOR PRESENTATION 17th Jan 2023 I- 1 tris
Slide 3: Eris proposes to acquire dermatology brands from Glenmark
ERIS PROPOSES TO ACQUIRE DERMATOLOGY BRANDS FROM GLENMARK • Eris proposes to acquire a portfolio of 9 Dermatology brands from Glenmark – these brands are Onabet, Halobate, Sorvate, Demelan, Luligee, Dosetil, Revize, Powercort and Aceret • Onabet, Halovate and Sorvate are ranked #1 in their respectiv
Slide 4: Financial and business highlights – Q3 FY23 and 9M FY23
FINANCIAL AND BUSINESS HIGHLIGHTS – Q3 FY 23 AND 9M FY 23 Q3 FY 23 9M FY 23 INR mn INR mn INR mn INR mn 4,233 1,372 32.4% 12,824 4,179 32.6% 27.4% Margin 23.2% Margin Op Revenue yoy growth EBITDA Op Revenue yoy growth EBITDA INR mn INR mn 1,002 23.7% Margin 3,127 24.4% Margin PAT PAT • Oaknet tracki
Slide 5: Q3 FY23 and 9M FY23 – entity wise margin profile
Q3 FY 23 AND 9M FY 23 – ENTITY WISE MARGIN PROFILE Q3 FY 23 9m FY 23 EBITDA Margin Entity Op Op YoY Gr EBITDA YoY Gr YoY Gr EBITDA YoY Gr 9m FY 23 9m FY 22 Revenue Revenue Eris (Standalone) 3,320 9% 1,264 3% 10,161 9% 3,936 3% 38.7% 41% Oaknet (BGx) 597 159 1,593 388 24.3% Aprica (BGx) 140 -5% 3 -90
Slide 6: Eris ranks among the top-10 fastest growing companies in Q3 FY23
ERIS RANKS AMONG THE TOP-10 FASTEST GROWING COMPANIES IN Q3 FY23 Eris has outperformed the IPM by 304 bps in Q3 FY23 19.5 17.3 17.1 16.7 15.9 a 14.8 14.7 14.5 14.4 13.4 11.6 IPM LA RENON GLENMARK INTAS ALKEM* ALEMBIC FDC ERIS LS ABBOTT* GSK EMCURE* Eris continues to be amongst the Top-10 companies (
Slide 7: Eris continues to grow ahead of the market in cardiometabolic and three emerging therapies
ERIS CONTINUES TO GROW AHEAD OF THE MARKET IN CARDIOMETABOLIC AND THREE EMERGING THERAPIES Eris grew at 14.7% in Q3 FY 23 vs. IPM growth of 11.6%; Outperformed IPM in 5 core therapies - Cardio-Metabolic, VMN, CNS & Women’s Health 1 L IPM Eris Cardio-Metabolic : 54% of Eris Emerging Specialties: 21%
Slide 8: 3-year CAGR of 48% in new-generation anti-diabetes therapies
3-YEAR CAGR OF 48% IN NEW-GENERATION ANTI-DIABETES THERAPIES Share of new generation (DPP4+SGLT2) therapies in Eris Anti-Diabetes Portfolio Eris revenue from DPP4+SGLT2 INR Crore Dec 2019 Dec 2022 CAGR 242 DPP4 + 48% SGLT2 DPP4 + 167 21% SGLT2 116 74 41% 59% 79% Dec 19 Dec 20 Dec 21 Dec 22 Legacy Le
Slide 9: Three emerging therapies (21% of revenue) grew at 22% for 9M FY23
THREE EMERGING THERAPIES (21% OF REVENUE) GREW AT 22% FOR 9M FY23 IPM Eris r" ) 1 I % Derma: 8% of Eris I I ) CNS : 7% of Eris Women’s Health : 6% of Eris ) 43.5 24.225.4 38.2 38.4 36.7 19.1 28.0 25.1 24.1 24.0 L 12.5 19.5 16.5 d 15.2 16.0 13.2 15.3 15.2 10.811.2 l413i 10.6 I j A I Q1 FY'23 Q2 FY'23
Slide 10: VMN market has bounced back; Eris grew ahead of market in Q3
VMN MARKET HAS BOUNCED BACK; ERIS GREW 658 BPS AHEAD OF MARKET IN Q3 VMN Segment : 17% of Eris ii IPM 58.9 48.1 Eris .• 35.8 19.2 9.8 12.2 14.5 14.1 10.7 12.5 14.8 12.7 il7.7 II 5.8 6.6 5.8 1.1 ME ME Iii=M a il -0.2 . -6.2 -6.4 il 73 . it -11.2 -12.4 41 FY21 42 FY21 43 FY21 44 FY21 41 FY'22 III Q2 F
Slide 11: Eris maintains high prescription ranking among doctor specialties
ERIS MAINTAINS HIGH PRESCRIPTION RANKING AMONG DOCTOR SPECIALTIES Eris Prescription Ranking* among Doctor Specialties 4 4 4 DIABETOLOGISTS # CARDIOLOGISTS NEUROLOGISTS 5 CONSULTING 7 5 GASTROENTEROLOGISTS PHYSICIANS DERMATOLOGISTS Source: SMSRC MAT Oct 2022 │* Rank in Represented Market including Oa
Slide 12: Power brands continue to have leading presence in core therapies (1/3)
POWER BRANDS CONTINUE TO HAVE LEADING PRESENCE IN CORE THERAPIES (1/3) Therapy wide presence in Oral Diabetes Care with power brands holding high ranks in Newer-generation fast-growing molecules Sulfonylurea Glitni5ave rank 6 in the ≈5,100 cr Glimepiride and combinations market Glimisave MV rank 2 i
Slide 13: Power brands continue to have leading presence in core therapies (2/3)
POWER BRANDS CONTINUE TO HAVE LEADING PRESENCE IN CORE THERAPIES (2/3) Strong presence in Anti-Hypertensives: the largest segment of Cardiac Care E ritel rank 5 in the ≈4,200 cr Telmisartan and combinations market Eritel CH rank 5 in Telmisartan + Chlorthalidone market Eritel LN rank 2 in Telmisarta
Slide 14: Power brands continue to have leading presence in core therapies (3/3)
POWER BRANDS CONTINUE TO HAVE LEADING PRESENCE IN CORE THERAPIES (3/3) Leading brands in Medical Dermatology Cosvate rank 1 in the ≈500 cr Clobetasol and combinations market 16% market share Cosvate-GM rank 1 Clobetasol + Gentamicin + Miconazole market Cosmelite rank 4 in Melasma Therapy Emerging pr
Slide 15: Q3 FY23 and 9M FY23 - standalone income statement
Q3 FY 23 AND 9M FY 23 - STANDALONE INCOME STATEMENT Standalone Q3 FY 23 9m FY 23 INR Millions Q3 FY 23 Q3 FY 22 yoy GR 9m FY 23 9m FY 22 yoy GR • Q3 FY23 standalone operating revenue of Rs. 332 crore, which represents a growth of 9% yoy Sale of Products 3,268 3,002 8.8% 9,988 9,167 9.0% Other Operat
Slide 16: Q3 FY23 and 9M FY23 - consolidated income statement
Q3 FY 23 AND 9M FY 23 - CONSOLIDATED INCOME STATEMENT Consolidated Q3 FY 23 9m FY 23 INR Millions Q3 FY 23 Q3 FY 22 yoy GR 9m FY 23 9m FY 22 yoy GR • Q3 consolidated operating revenue Rs. 423 cr, Sale of Products 4,178 3,281 27.4% 12,652 10,251 23.4% which represents a growth of 27.4% YoY. Other Ope
Slide 17: Eris continues to execute successfully on growth drivers (1/2)
ERIS CONTINUES TO EXECUTE SUCCESSFULLY ON GROWTH DRIVERS (1/2) • 1 Expansion of power- brands’ franchise • Our business model of building strong and sustainable brands enables us to consistently outperform the market • Eris delivered a growth of 15% in Q3 FY23 vs. a market growth of 12% • Eris deliv
Slide 18: Eris continues to execute successfully on growth drivers (2/2)
ERIS CONTINUES TO EXECUTE SUCCESSFULLY ON GROWTH DRIVERS (2/2) • 3 Expansion of physician coverage • We continue to make good progress in expanding our coverage of Specialists and Consulting Physicians in line with our expectations • • We have added ~ 200 Reps to the Eris field-force since the start
Slide 19: Shareholder profile
SHAREHOLDER PROFILE Shareholding of Promoters and Top 15 Institutional Investors Others As on As on As on FPIs 0.4% Name of Shareholder 31-Dec-22 30-Sep-22 30-Jun-22 15.5% 648* 711* 667* Promoters 52.70% 52.29% 52.30% 1 Chrys Capital (Emerald Investment Limited) 7.58% 7.58% 7.58% 2 UTI Mutual Fund 5
Slide 20: Safe harbor statement
SAFE HARBOR STATEMENT This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward- looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and the underlying assumptions
Slide 21: Thank you
Eris ERIS LIFESCIENCES LIMITED THANK YOU KRUTI RAVAL INVESTOR RELATIONS kruti@erislifesciences.com 20 Kris